<DOC>
	<DOCNO>NCT00002993</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy mitomycin , doxorubicin , cisplatin treat patient recurrent advanced cancer uterus .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Recurrent Advanced Cancer Uterus</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate antitumor activity combination mitomycin , doxorubicin , cisplatin ( MAP ) patient recurrent advanced uterine sarcoma . II . Determine nature degree toxicity MAP chemotherapy cohort patient . OUTLINE : Patients receive IV doxorubicin , mitomycin , cisplatin 3 hour every 3 week , minimum 1 course . Patients complete response , partial response , stable disease continue least 3 course . If side effect severe , patient may remain study regimen investigator 's discretion maximum 6 course . All patient follow death . PROJECTED ACCRUAL : The first stage accrual anticipate accrue 20 evaluable patient approximately 12 month . If indicate , second stage accrue approximately 10 evaluable patient .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced , persistent , recurrent uterine sarcoma Documented disease progression local therapy Measurable disease consist abdominal , pelvic , chest , mass define least two dimension palpation , xray , compute tomography ultrasound PATIENT CHARACTERISTICS : Age : No age specify Performance status : Karnofsky 50 % 100 % Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time normal SGOT great 3 time normal Alkaline phosphatase great 3 time normal Renal : Creatinine great 1.5 time normal Cardiovascular : Ejection fraction within institutional normal limit Pulmonary : Not specify Other : No active infection No concurrent second malignancy nonmelanoma skin cancer Must disease free prior malignancy least 5 year receive treatment chemotherapy radiation therapy malignancy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 6 week since radiotherapy Recovered effect radiotherapy Surgery : Recovered effect surgery</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
</DOC>